Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zhuang, Jianhui ^a   Peng, Wenhui ^a   Li, Hailing ^a   Lu, Yuyan ^a   Wang, Ke ^a   Fan, Fan ^b   Li, Shuang ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; GELATINASE B; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FOAM CELLS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VINCA ALKALOIDS;

EID: 84891940639     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082509     Document Type: Article

References (41)

1. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126. doi:10.1056/NEJM199901143400207. PubMed: 9887164.
2. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V et al. (2004) Terminology for high-risk and vulnerable coronary artery plaques. Report of a Meeting on the Vulnerable Plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 25: 1077-1082. doi:10.1016/j.ehj. 2004.01.002. PubMed: 15191780.
3. Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM et al. (2011) Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 106: 1-19. doi: 10.1160/TH10-12-0784. PubMed: 21670845.
4. Xu J, Zou MH (2009) Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120: 1266-1286. doi: 10.1161/CIRCULATIONAHA.108.835223. PubMed: 19786641.
5. Manduteanu I, Voinea M, Antohe F, Dragomir E, Capraru M et al. (2003) Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 477: 269-276. doi:10.1016/j.ejphar. 2003.08.016. PubMed: 14522366. (Pubitemid 38366400)
6. Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145: 341-355. doi:10.1016/j.cell.2011.04.005. PubMed: 21529710.
7. Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 28: 2108-2114. doi:10.1161/ATVBAHA.108.173898. PubMed: 18772495.
8. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM et al. (2004) Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 24: 733-738. doi:10.1161/01.ATV.0000121571.78696.dc. PubMed: 14962945. (Pubitemid 38451612)
9. Johnson JL, Fritsche-Danielson R, Behrendt M, Westin-Eriksson A, Wennbo H et al. (2006) Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 71: 586-595. doi:10.1016/j.cardiores.2006.05.009. PubMed: 16759648. (Pubitemid 44107863)
10. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ et al. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089-2099. doi:10.1056/NEJMoa1206797. PubMed: 23126252.
11. Cai Y, Miller CL, Nagel DJ, Jeon KI, Lim S et al. (2011) Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 31: 616-623. doi:10.1161/ATVBAHA.110.212621. PubMed: 21148428.
12. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100: 309-327. doi:10.1161/01.RES.0000256354.95791.f1. PubMed: 17307970.
13. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90: 151-157. doi:10.1161/hh0202.104108. PubMed: 11834707. (Pubitemid 34627083)
14. Lee JH, Oh GT, Park SY, Choi JH, Park JG et al. (2005) Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313: 502-509. PubMed: 15734902. (Pubitemid 40604148)
15. Kukreja RC, Salloum FN, Das A (2012) Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol 59: 1921-1927. doi:10.1016/j.jacc. 2011.09.086. PubMed: 22624832.
16. Lee SW, Park SW, Kim YH, Yun SC, Park DW et al. (2011) A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions). Trial-J Am Coll Cardiol 57: 1264-1270. doi: 10.1016/S0735-1097(11)61264-3.
17. Lörincz C, Szász K, Kisfaludy L (1976) The synthesis of ethyl apovincaminate. Arzneimittelforschung 26: 1907. PubMed: 1037211.
18. Bonoczk P, Gulyas B, Adam-Vizi V, Nemes A, Karpati E et al. (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain. Res Bull 53: 245-254.
19. Dunkern TR, Hatzelmann A (2007) Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J 274: 4812-4824. doi:10.1111/j.1742-4658.2007.06001.x. PubMed: 17697115. (Pubitemid 47353125)
20. Zhou X, Dong XW, Crona J, Maguire M, Priestley T (2003) Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 306: 498-504. doi:10.1124/jpet.103.051086. PubMed: 12730276. (Pubitemid 36886146)
21. Sitges M, Galván E, Nekrassov V (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int 46: 533-540. doi: 10.1016/j.neuint.2005.02.001. PubMed: 15843047. (Pubitemid 40544400)
22. Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M et al. (2005) Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 229-230: 275-284. doi:10.1016/j.jns.2004.11.053. PubMed: 15760651. (Pubitemid 40341594)
23. Bagoly E, Fehér G, Szapáry L (2007) The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv Hetil 148: 1353-1358. doi:10.1556/OH.2007.28115. PubMed: 17631470. (Pubitemid 47490190)
24. Cai Y, Knight WE, Guo S, Li JD, Knight PA et al. (2012) Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J Pharmacol Exp Ther 343: 479-488. doi:10.1124/jpet.112.195446. PubMed: 22915768.
25. Huang EW, Xue SJ, Zhang Z, Zhou JG, Guan YY et al. (2012) Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis 17: 1120-1130. doi:10.1007/s10495-012-0743-0. PubMed: 22729609.
26. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H et al. (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A 107: 9795-9800. doi:10.1073/pnas.0914414107. PubMed: 20448200.
27. Mitra S, Khaidakov M, Lu J, Ayyadevara S, Szwedo J et al. (2011) Prior exposure to oxidized low-density lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. Am J Physiol Heart Circ Physiol 301: H506-H513. doi: 10.1152/ajpheart.00252.2011. PubMed: 21602467.
28. Li H, Peng W, Jian W, Li Y, Li Q et al. (2012) ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol 11: 65. doi: 10.1186/1475-2840-11-65. PubMed: 22694757.
29. Zhuang J, Peng W, Li H, Wang W, Wei Y et al. (2012) Methylation of p15INK4b and expression of ANRIL on chromosome 9p21 are associated with coronary artery disease. PLOS ONE 7: e47193. doi: 10.1371/journal.pone.0047193. PubMed: 23091611.
30. Shah PK (2003) Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41: 15S-22S. doi:10.1016/S0735-1097(03)80064-5. PubMed: 12644336. (Pubitemid 36223342)
31. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A (2011) Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31: 969-979. doi:10.1161/ATVBAHA.110.207415. PubMed: 21508343.
32. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695. doi:10.1056/NEJMra043430.PubMed: 15843671.
33. Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581. doi:10.1152/physrev.00024.2005. PubMed: 16601268.
34. Steinberg D (1997) Lewis A Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 95: 1062-1071. doi: 10.1161/01.CIR.95.4.1062. PubMed: 9054771. (Pubitemid 27091554)
35. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J (2000) Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20: 698-702. doi:10.1161/01.ATV. 20.3.698. PubMed: 10712393. (Pubitemid 30151683)
36. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF et al. (2006) Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37: 235-239. doi:10.1161/01.STR.0000196986.50059.e0. PubMed: 16339461. (Pubitemid 43732079)
37. Mohamed JS, Boriek AM (2012) Loss of desmin triggers mechanosensitivity and up-regulation of Ankrd1 expression through Akt-NF-kappaB signaling pathway in smooth muscle cells. FASEB J 26: 757-765. doi:10.1096/fj.10-160291. PubMed: 22085644.
38. Shao R, Tsai EM, Wei K, von Lindern R, Chen YH et al. (2001) E1A inhibition of radiation-induced NF-kappaB activity through suppression of IKK activity and IkappaB degradation, independent of Akt activation. Cancer Res 61: 7413-7416. PubMed: 11606372. (Pubitemid 32995026)
39. Kemény V, Molnár S, Andrejkovics M, Makai A, Csiba L (2005) Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol 45: 1048-1054. doi:10.1177/0091270005279363. PubMed: 16100299. (Pubitemid 41192364)
40. Medina AE (2010) Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci U S A 107: 9921-9922. doi:10.1073/pnas. 1005138107. PubMed: 20495091.
41. Miskolczi P, Vereczkey L, Szalay L, Göndöc C (1987) Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid. Eur J Clin Pharmacol 33: 185-189. doi:10.1007/BF00544565. PubMed: 3691609. (Pubitemid 17149233)